Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center

Few data are available on the safety of COVID-19 vaccines in cancer patients undergoing active cancer-directed treatment. This case series analyzes outcomes in terms of adverse events in 5297 patients undergoing anti-cancer treatment who were vaccinated with anti-SARS-CoV-2 Pfizer-BioNTech vaccine a...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2022-03, Vol.27 (2), p.e203-e205
Main Authors: Brunello, Antonella, Guarneri, Valentina, Coppola, Marina, Bernardi, Matteo, Ottolitri, Ketti, Ghi, Maria Grazia, Mioranza, Eleonora, Vianello, Federica, Gottardi, Michele, Lonardi, Sara, Zagonel, Vittorina
Format: Article
Language:English
Subjects:
Adverse Drug Reaction Reporting Systems
Analysis
BNT162 Vaccine
Brief Communications
Cancer
Cancer patients
Care and treatment
Chemotherapy
Complications and side effects
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
Drug therapy
Drug-Related Side Effects and Adverse Reactions
Hematologic Neoplasms
Humans
Pharmaceutical industry
RNA
Safety and security measures
Vaccination
Vaccines
Vaccines - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Few data are available on the safety of COVID-19 vaccines in cancer patients undergoing active cancer-directed treatment. This case series analyzes outcomes in terms of adverse events in 5297 patients undergoing anti-cancer treatment who were vaccinated with anti-SARS-CoV-2 Pfizer-BioNTech vaccine at a single cancer center from March 6, 2021 to May 9, 2021. Adverse events were retrieved from the national Italian pharmacovigilance platform (http://www.vigicovid.it). Of the 5297 patients treated for either solid tumors (87%) or onco-hematologic malignancies (13%) who were vaccinated, 8 adverse drug reactions (ADRs) were reported. One was a severe ADR and 7 were non-severe ADRs. Non-severe ADRs resolved within 48 hours. BNT162b2 Pfizer-BioNTech vaccine was safely administered in the largest cohort of cancer patients reported to date.
ISSN:1083-7159
1549-490X
DOI:10.1093/oncolo/oyab037